PubMed ID: 37367722 Author(s): Mehta N, Patil S, Modi V, Vardi R, Liu K, Singh RP, Sarraf D, Oden NL, VanVeldhuisen PC, Scott IU, Ip MS, Blodi BA, Modi Y. High Variation in Inner Retinal …
Barbara Blodi
SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes.
PubMed ID: 36584835 Author(s): Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Investigator Group. SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes. Am J Ophthalmol. …
Retinal Thickness and Morphology Changes on OCT in Youth with Type 2 Diabetes: Findings from the TODAY Study.
PubMed ID: 36531589 Author(s): Mititelu M, Uschner D, Doherty L, Bjornstad P, Domalpally A, Drews KL, Gubitosi-Klug R, Levitsky LL, Pak JW, White NH, Blodi BA. Retinal thickness and morphology changes on OCT in youth …
Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion.
PubMed ID: 35461831 Author(s): Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA; SCORE2 Investigator Group. Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central …
SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion.
PubMed ID: 34842984 Author(s): Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Investigator Group. SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion. Graefes Arch Clin …
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
PubMed ID: 35323843 Author(s): Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group. Baseline characteristics and outcomes after Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in participants with Hemiretinal …
Disease-modifying effects of ranibizumab for central retinal vein occlusion.
PubMed ID: 34613454 Author(s): Huang JM, Khurana RN, Ghanekar A, Wang PW, Day BM, Blodi BA, Domalpally A, Quezada-Ruiz C, Ip MS. Disease-modifying effects of ranibizumab for central retinal vein occlusion. Graefes Arch Clin Exp …
Comparison of ETDRS 7-Field to 4-Widefield Digital Imaging in the Evaluation of Diabetic Retinopathy Severity.
PubMed ID: 35015059 Author(s): Blodi BA, Domalpally A, Tjaden AH, Barrett N, Chew EY, Knowler WC, Lee CG, Pi-Sunyer X, Wallia A, White NH, Temprosa M. Comparison of ETDRS 7-field to 4-widefield digital imaging in …
AI-based monitoring of retinal fluid in disease activity and under therapy.
PubMed ID: 34166808 Author(s): Schmidt-Erfurth U, Reiter GS, Riedl S, Seeböck P, Vogl WD, Blodi BA, Domalpally A, Fawzi A, Jia Y, Sarraf D, Bogunović H. AI-based monitoring of retinal fluid in disease activity and …